The future of the weight loss market might not revolve around GLP-1 drugs.

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

The popularity of GLP-1 weight loss drugs has soared, which had created a shortage among many of the drugs, including Eli ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

With the addition of compounded semaglutide [GLP-1], we are expanding our offering to include a clinical weight management ...

Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs ...

As prices for Ozempic have risen in recent months, many people may be seeking cheaper alternatives for managing diabetes or ...

Research highlights how GLP-1 receptor agonists may improve brain health by targeting the neurovascular unit, linking ...